Literature DB >> 11442483

Anti-beta 2 glycoprotein 1 and anti-annexin V antibodies in women with recurrent miscarriage.

J Arnold1, Z Holmes, W Pickering, C Farmer, L Regan, H Cohen.   

Abstract

While it has been established that anti-phospholipid antibodies (aPL) are associated with recurrent miscarriage (RM), the importance of anti-beta2 glycoprotein 1 (GP1) IgG and anti-annexin V IgG antibodies as risk factors for RM is undefined. We have investigated the prevalence of anti-beta2 GP1 IgG and anti-annexin V IgG antibodies in 54 aPL-positive and 48 aPL-negative women with RM. The prevalence of IgG anti-beta2 GP1 antibodies was not significantly different in persistently aPL-positive women with RM (7%), aPL-negative women with RM (6%) and the normal parous control group (3%). Anti-annexin V IgG antibody prevalence was significantly increased in aPL-positive women with RM compared with aPL-negative women with RM (P = 0.01). The elevations were found in 35%, 19% and 16% of aPL-positive women with RM, aPL-negative women with RM and the control group respectively. No women showed positivity for both anti-beta2 GP1 IgG and anti-annexin V antibodies. Anti-beta2 GP1 IgG antibodies do not appear to be contributory to the investigation of women with RM. Anti-annexin V antibody positivity, although associated with aPL positivity in women with RM, is not an independent risk marker.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11442483     DOI: 10.1046/j.1365-2141.2001.02812.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  13 in total

Review 1.  Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers.

Authors:  Shruti Chaturvedi; Keith R McCrae
Journal:  Curr Rheumatol Rep       Date:  2017-07       Impact factor: 4.592

2.  Levels of folate receptor autoantibodies in maternal and cord blood and risk of neural tube defects in a Chinese population.

Authors:  Na Yang; Linlin Wang; Richard H Finnell; Zhiwen Li; Lei Jin; Le Zhang; Robert M Cabrera; Rongwei Ye; Aiguo Ren
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2016-05-11

3.  Anti-annexin A5 antibodies and 25-hydroxy-cholecalciferol in female patients with primary antiphospholipid syndrome.

Authors:  Mirjana Bećarević; Marija Sarić; Ljudmila Stojanovich; Duško Mirković; Violeta Dopsaj; Svetlana Ignjatović
Journal:  Clin Rheumatol       Date:  2018-06-12       Impact factor: 2.980

Review 4.  The IgG and IgM isotypes of anti-annexin A5 antibodies: relevance for primary antiphospholipid syndrome.

Authors:  Mirjana Bećarević
Journal:  J Thromb Thrombolysis       Date:  2016-11       Impact factor: 2.300

5.  Evaluation of the clinical relevance of anti-annexin-A5 antibodies in Chinese patients with antiphospholipid syndrome.

Authors:  Shulan Zhang; Ziyan Wu; Jing Li; Xiaoting Wen; Liubing Li; Wen Zhang; Jiuliang Zhao; Fengchun Zhang; Yongzhe Li
Journal:  Clin Rheumatol       Date:  2016-12-21       Impact factor: 2.980

Review 6.  Recent advances in the diagnosis of antiphospholipid syndrome.

Authors:  Hyun-Sook Chi
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

7.  Annexin A5 polymorphism (-1C-->T) and the presence of anti-annexin A5 antibodies in the antiphospholipid syndrome.

Authors:  B de Laat; R H W M Derksen; I J Mackie; M Roest; S Schoormans; B J Woodhams; P G de Groot; W L van Heerde
Journal:  Ann Rheum Dis       Date:  2006-01-31       Impact factor: 19.103

8.  Anti-annexin V antibodies in Takayasu's arteritis: prevalence and relationship with disease activity.

Authors:  N K Tripathy; N Sinha; S Nityanand
Journal:  Clin Exp Immunol       Date:  2003-11       Impact factor: 4.330

9.  Elevated plasminogen activator inhibitor type-1 (PAI-1) as contributing factor in pathogenesis of hypercoagulable state in antiphospholipid syndrome.

Authors:  N K Singh; A Gupta; Dibya R Behera; D Dash
Journal:  Rheumatol Int       Date:  2013-03-22       Impact factor: 2.631

10.  Bouquet variety of antiphospholipid antibodies in recurrent pregnancy loss.

Authors:  Marta P Baleva; Zhivka P Karagyozova; Milena K Nikolova-Vlahova; Krasimir V Nikolov; Petar K Nikolov
Journal:  Cent Eur J Immunol       Date:  2014-10-14       Impact factor: 2.085

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.